CO2023014991A2 - Cationic lipids based on good buffers - Google Patents
Cationic lipids based on good buffersInfo
- Publication number
- CO2023014991A2 CO2023014991A2 CONC2023/0014991A CO2023014991A CO2023014991A2 CO 2023014991 A2 CO2023014991 A2 CO 2023014991A2 CO 2023014991 A CO2023014991 A CO 2023014991A CO 2023014991 A2 CO2023014991 A2 CO 2023014991A2
- Authority
- CO
- Colombia
- Prior art keywords
- cationic lipids
- lipids based
- good buffers
- compounds
- cationic
- Prior art date
Links
- 125000002091 cationic group Chemical group 0.000 title abstract 2
- 239000006173 Good's buffer Substances 0.000 title 1
- 238000001727 in vivo Methods 0.000 abstract 2
- -1 class of cationic lipid compounds Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 231100000755 favorable toxicity profile Toxicity 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona, entre otras cosas, una nueva clase de compuestos lipídicos catiónicos (por ejemplo, lípidos catiónicos que tienen una estructura de acuerdo con la fórmula (I)) para la administración in vivo de agentes terapéuticos, tales como los ácidos nucleicos. Se contempla que estos compuestos son capaces de un suministro in vivo altamente efectiva mientras mantienen un perfil de toxicidad favorable.The present invention provides, among other things, a new class of cationic lipid compounds (for example, cationic lipids having a structure according to formula (I)) for the in vivo administration of therapeutic agents, such as nucleic acids. It is contemplated that these compounds are capable of highly effective in vivo delivery while maintaining a favorable toxicity profile.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163175429P | 2021-04-15 | 2021-04-15 | |
| US202263313578P | 2022-02-24 | 2022-02-24 | |
| PCT/US2022/025067 WO2022221688A1 (en) | 2021-04-15 | 2022-04-15 | "good"buffer-based cationic lipids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023014991A2 true CO2023014991A2 (en) | 2024-02-05 |
Family
ID=88412572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0014991A CO2023014991A2 (en) | 2021-04-15 | 2023-11-03 | Cationic lipids based on good buffers |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4323346A1 (en) |
| JP (1) | JP2024514326A (en) |
| KR (1) | KR20230171974A (en) |
| AU (1) | AU2022259686A1 (en) |
| BR (1) | BR112023020027A2 (en) |
| CA (1) | CA3215137A1 (en) |
| CO (1) | CO2023014991A2 (en) |
| IL (1) | IL307652A (en) |
| MX (1) | MX2023012195A (en) |
-
2022
- 2022-04-15 IL IL307652A patent/IL307652A/en unknown
- 2022-04-15 MX MX2023012195A patent/MX2023012195A/en unknown
- 2022-04-15 CA CA3215137A patent/CA3215137A1/en active Pending
- 2022-04-15 EP EP22721587.8A patent/EP4323346A1/en active Pending
- 2022-04-15 BR BR112023020027A patent/BR112023020027A2/en unknown
- 2022-04-15 JP JP2023562945A patent/JP2024514326A/en active Pending
- 2022-04-15 KR KR1020237039000A patent/KR20230171974A/en unknown
- 2022-04-15 AU AU2022259686A patent/AU2022259686A1/en active Pending
-
2023
- 2023-11-03 CO CONC2023/0014991A patent/CO2023014991A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4323346A1 (en) | 2024-02-21 |
| KR20230171974A (en) | 2023-12-21 |
| MX2023012195A (en) | 2023-12-15 |
| BR112023020027A2 (en) | 2023-11-14 |
| CA3215137A1 (en) | 2022-10-20 |
| AU2022259686A1 (en) | 2023-11-30 |
| JP2024514326A (en) | 2024-04-01 |
| IL307652A (en) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021014831A2 (en) | Ionizable amine lipids and lipid nanoparticles | |
| CO2021005774A2 (en) | Ionizable amine lipids | |
| CO2021008838A2 (en) | Modified amine lipids | |
| CO2022002685A2 (en) | Enhanced Lipid Nanoparticles for Nucleic Acid Delivery | |
| CY1124499T1 (en) | LIPIDS FOR THERAPEUTIC AGENT DELIVERY COMPOSITIONS | |
| CO2019011762A2 (en) | Compounds that inhibit mcl-1 protein | |
| ECSP14012527A (en) | DPA-ENRICHED COMPOSITIONS OF POLYINSATURATED OMEGA 3 FATTY ACIDS IN FREE ACID FORM | |
| CU20190073A7 (en) | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | |
| EA201891018A1 (en) | LIPIDS AND LIPID COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | |
| CL2016001809A1 (en) | 11-hydroxyl derivatives of bile acids and amino acid conjugates thereof as farnesoid receptor modulators x (divisional sol. No. 3344-15). | |
| AR078850A1 (en) | THERAPEUTIC COMPOSITIONS CONCENTRATED OF PHOSPHOLIPIDS | |
| GT201500030A (en) | 1,4-DISPOSED PIRIDAZINE ANALOGS AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO THE DEFICIENCY OF SMN | |
| CR20180232A (en) | PEPTIDE MACROCICLES AGAINST ACINETOBACTER BAUMANNII | |
| UY37168A (en) | PROPHARMS OF ACTIVE CYTOTOX PRINCIPLES WITH ENZYMATICALLY SCINDIBLE GROUPS | |
| EA201490921A1 (en) | SUSTAINABLE COMPOSITIONS WITH CONTROLLED SHIPPING | |
| UY35273A (en) | TIADIAZOL, ANALOGS OF THE SAME, AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO DEFICIENT OF SMN | |
| GT201200004A (en) | FUSIONATED IMIDAZOLS AND COMPOSITIONS THAT CONTAIN THEM FOR THE TREATMENT OF PARASITARY DISEASES, AS BY MALARIA EXAMPLE | |
| ECSP11010807A (en) | SALTS OF HIV INHIBITOR COMPOUNDS | |
| CO2023018231A2 (en) | Novel therapeutic administration residues and uses of these | |
| BR112021025477A2 (en) | Parenteral lysophosphatidylcholine formulations like lpc-dha, lpc-epa and their uses in therapy | |
| CL2018001631A1 (en) | Alkyl dihydroquinolinsulfonamide compounds | |
| CO2023014991A2 (en) | Cationic lipids based on good buffers | |
| CU20130027A7 (en) | CHEMICAL CHAPERONINS AS NEW MOLECULAR MODULATORS OF THE BETA PROTEIC AGGREGATION PRESENT IN THE CONFORMATIONAL DISEASES | |
| ECSP23070418A (en) | STING MODULATORS (STIMULATOR OF INTERFERON GENES) | |
| CU20190028A7 (en) | USEFUL INDAZOLE COMPOUNDS IN LIGAMENT AND / OR TENDON INJURIES |